Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] - N0000191009

Pharmacologic Code	N0000191009
Pharmacologic Name	Vascular Endothelial Growth Factor Receptor 2 Antagonist
Pharmacologic Uses	human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 2 products whose active ingredient are classified under the same pharmacologic class Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0002-7669	Cyramza	Non-Proprietary Name: Ramucirumab	Solution	Intravenous	Eli Lilly And Company	ACTIVE
	0002-7678	Cyramza	Non-Proprietary Name: Ramucirumab	Solution	Intravenous	Eli Lilly And Company	ACTIVE